Molecular Docking Analysis of Zerumbone Derivatives as XIAP-BIR3 Inhibitor for Anticancer Agent
DOI:
https://doi.org/10.11594/nstp.2024.4602Keywords:
In silico, zerumbone, cancer, XIAP-BIR3Abstract
Cancer is the second most common cause of death worldwide. Common therapies used to treat cancer include radiation, chemotherapy, and surgery. However, resistance to treatment often gives a challenging problem, and new alternative therapies derived from natural compounds are needed. Zerumbone is terpenoid compound with various biological activities, including anti-tumor and anti-cancer. This study aims to investigate the activity of Zerumbone and its derivatives against the XIAP-BIR3 protein. The target protein used PDB ID: 4KMP as inhibitor of XIAP-BIR3. There are 21 zerumbon derivatives retrieved from published article. Docking of zerumbone derivatives was performed using Autodock 1.5.6. Molecular docking result showed derivative 6 of Zerumbone has potential as an anti-cancer agent with a binding energy of -7.84 kcal/mol; meanwhile, the reference inhibitor has a binding energy of -5.21 kcal/mol. These results of the study indicate that the development of inhibitor XIAP-BIR3 may be a potential strategy in cancer treatment and zerumbone derivatives are predicted to be potential candidates that can be analyzed further.
Downloads
Downloads
Published
Conference Proceedings Volume
Section
License
Copyright (c) 2024 Winni Nur Auli, Nisa Yulianti Suprahman, Riri Fauziyya, Sarmoko, Arif Ashari, Safia Fazila, Qurrota A`yun Azzahrah, Romualdo Pasaribu, Putri Liswatini, Ihza Adzkiya Mubarak Al-Husni, Dinda Naila Dhiya Salsabila
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this proceedings agree to the following terms:
Authors retain copyright and grant the Nusantara Science and Technology Proceedings right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this proceeding.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the proceedings published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this proceeding.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See the Effect of Open Access).
